Nurse Practitioner Certification
f f f
Examination and Practice Preparation
f f f f f
Testbank by Margaret A. Fitzgerald
f f f f f
,HealthPromotion f
and Disease Prevention
f f
6. Active f immunity f is f defined f as:
A. resistance f developed f in f response f to f an f antigen.
B. immunity fconferred fby fan fantibody fproduced fin
fanother fhost.
1. An fexample fof fa fprimary fprevention fmeasure ffor fa78- C. the fresistance fof fa fgroup fto fan finfectious fagent.
fyear-old fman f with fchronic f obstructive
D. defense fagainst fdisease facquired fnaturally fby fthe
fpulmonary fdisease fis:
finfant ffrom fthe fmother.
A. reviewing f the f use f of f prescribed f medications.
B. conducting f a f home f survey f to f minimize f fall f risk. 7. Which fof fthe ffollowing fis fusually fviewed fas fthe fmost
C. checking fFEV1 f(force fexpired fvolume fat f1 fsecond) fcost-effective fform fof fhealthcare?
fto fFVC f(forced fvital fcapacity) fratio. A. primary f prevention
D. ordering ffecal foccult fblood ftest f(FOBT). B. secondary f prevention
C. tertiary f prevention
2. Which fof fthe ffollowing fis fan fexample fof fa fprimary fpreven- D. cancer-reduction f measures
ftion factivity fin fa f76-year-old fwoman fwith fosteoporosis?
A. bisphosphonate f therapy 8. An f18-year-old fwoman fwith fallergic frhinitis fpresents ffor
B. calcium f supplementation fprimary fcare. fShe fis fsexually factive fwith fa fmale fpartner
C. ensuring fadequate fillumination fin fthe fhome fand fis f1 fyear fpost-coitarche; fduring fthis ftime fshe fhad
fhad ftwo fsex fpartners. fAn fexample fof fa fprimary
D. use fof fa fback fbrace
fprevention factivity ffor fthis fpatient fis:
3. Secondary fprevention fmeasures ffor fa f78-year-old fman A. screening f for f sexually f transmitted f infection.
fwith fchronic fobstructive fpulmonary fdisease finclude:
B. counseling f about f safer f sexual f practices.
A. screening ffor fmood fdisorders. C. prescribing f therapies f for f minimizing f allergy.
B. administering f influenza f vaccine.
D. obtaining f a f liquid-based f Papanicolaou f (Pap) f test.
C. obtaining f a f serum f theophylline f level.
D. advising fabout fappropriate fuse fof fcar fpassenger 9. When fa fcritical fportion fof fa fcommunity fis fimmunized
frestraints. fagainst fa fcontagious fdisease, fmost fmembers fof fthe
fcom- fmunity, feven fthe funimmunized, fare fprotected
4. Tertiary fprevention fmeasures ffor fa f69-year-old fwoman fagainst fthat fdisease fbecause fthere fis flittle fopportunity
fwith fheart ffailure finclude:
ffor fan foutbreak. fThis fis fknown fas immunity.
A. administering f antipneumococcal f vaccine. A. passive
B. adjusting f therapy f to f minimize f dyspnea. B. humoral
C. surveying f skin f for f precancerous f lesions. C. epidemiologic
D. reviewing f safe f handling f of f food. D. community
5. Which f of f the f following f products f provides f passive
immunity?
f f f f
f 1. f B. 4. f B. 7. f A.
2. f C. 5. f A. 8. f B.
3. f A. 6. f A. 9. f D.
1
,2 C fHfA fP fT fE fR f f 1 ■ f f Health f Promotion f and f Disease f Prevention
Primary fprevention fmeasures finclude factivities fprovided
fto findividuals fto fprevent fthe fonset for facquisition fof fa fgiven
fdisease. fThe fgoal fof fprimary fprevention fmeasures fis fto fspare
findividuals fthe fsuffering, fburden, fand fcost fassociated fwith fthe
clinical fcondition fand fis fthe ffirst flevel fof fhealthcare. fAn fex- 10. When fadvising fa fpatient fabout finjectable finfluenza fim-
fample fis fhealth-protecting feducation fand fcounseling, fsuch fmunization, fthe fnurse fpractitioner f(NP) fconsiders fthe
fas fencouraging fthe fuse fof fcar frestraints fand fbicycle ffollowing fabout fthe fuse fof fthis fvaccine:
fhelmets, fcounseling fabout fsafer fsexual fpractices, fand A. Its fuse fis fnot frecommended fin fsickle fcell fanemia.
fproviding finfor- fmation fon faccident fand ffall fprevention. B. Its fuse fis flimited fto fchildren folder fthan f2 fyears.
fGiven fits ffocus fon fpreventing fillness for finjury, fprimary C. Its f use f is f limited f due f to f containing f live f virus.
fprevention fis fusually fviewed fas fthe fmost feffective fform D. Its fuse fis frecommended ffor fvirtually fall fmembers fof
fof fhealthcare. fthe fpopulation.
Immunizations fand fchemoprophylaxis fare falso fexam-
fples fof fprimary fprevention fmeasures. fActive fimmunization
11. A fmiddle-aged fman fwith fchronic fobstructive fpul-
fmonary fdisease fwho fis fabout fto freceive finjectable fin-
fthrough fthe fuse fof fvaccines fprovides flong-term fprotection
ffluenza fvaccine fshould fbe fadvised fthat:
ffrom fdisease. fIn fherd for fcommunity fimmunity, fa
A. it fis fmore fthan f90% feffective fin fpreventing finfluenza.
fsignificant fportion fof fa fgiven fpopulation fhas fimmunity
fagainst fan finfec- ftious fagent; fthe flikelihood fthat fthe
B. its fuse fis fcontraindicated fin fthe fpresence fof fpsoriasis
fvulgaris.
fsusceptible fportion fof fthe fgroup fwould fbecome finfected fis
C. localized freactions fsuch fas fsoreness fand fredness fat
fminimized f(Fig. f1–1). fPas- fsive fimmunity fis fprovided fwhen
fthe fsite fof fthe fimmunization fare ffairly
fa fperson freceives fselect fan- ftibodies, fusually fvia fthe
fcommon.
fadministration fof fimmune fglobulin f(IG), fafter fexposure fto
fan finfective fagent. fThis fimmunity fis ftemporary fand
D. a fshort, fintense, fflulike fsyndrome ftypically foccurs
fafter fimmunization.
frequires fthe fpatient fto fpresent fpost-exposure; fthe fprotection
fprovided fby fIG fusually fstarts fwithin fhours f of freceiving fthe 12. A f44-year-old fwoman fwith fasthma fpresents fasking ffor
fdoses fand flasts fa fnumber fof fmonths. fThe fuse fof fvaccines fto fa f‚flu fshot.‛ fShe fis fseen ftoday ffor fan furgent fcare fvisit, fis
fproduce flasting fdisease fprotection fis fpreferred fto fpassive fdiagnosed fwith fa flower furinary ftract finfection, fand fis
fimmunization fthrough fthe fuse fof fIG. fAnother fexam- fple fof fprescribed ftrimethoprim-sulfamethoxazole. fShe fis
fpassive fimmunity fis fthe facquisition fof fdisease fprotec- ftion fwithout ffever for fgastrointestinal fupset fwith fstable
fprovided ffrom fmother fto funborn fchild fvia fthe fplacenta. frespiratory fstatus. fYou finform fher fthat fshe:
fSecondary fprevention fmeasures finclude factivities fprovided A. should freturn ffor fthe fimmunization fafter fcomplet-
fto fidentify fand ftreat fasymptomatic fpersons fwho fhave frisk ffac- fing fher fantibiotic ftherapy.
ftors ffor fa fgiven fdisease for fin fpreclinical fdisease. fExamples fin- B. would flikely fdevelop fa fsignificant freaction fif fimmu-
fclude fscreening fexaminations ffor fpreclinical fevidence fof fnized ftoday.
fcancer, fsuch fas fmammography fand fcervical fexamination fwith C. can f receive f the f immunization f today.
f a fPapanicolaou ftest. fOther fexamples fof fsecondary D. is fnot fa fcandidate ffor fany fform fof finfluenza fvaccine.
fprevention factivities finclude fscreening ffor fclinical fconditions
13. Which fof fthe ffollowing fstatements fbest fdescribes
fwith fa fpro- ftracted fasymptomatic fperiod, fsuch fas fa fblood
famantadine for frimantadine fuse fin fthe fcare fof
fpressure fmeas- furement fto fdetect fhypertension fand fa flipid
fpatients fwith for fat frisk ffor finfluenza?
fprofile fto fdetect fhyperlipidemia f(Table f1–1).
A. Significant fresistance fto fselect fstrains fof finfluenza
See ffull fcolor fimages fof fthis ftopic flimits fthe fusefulness fof fthese fmedications.
fon f DavisPlus f at B. The fprimary faction fof fthese ftherapies fis fin fprevent-
f http://davisplus.fadavis.com f|
fing finfluenza fA fduring foutbreaks.
fKeyword: fFitzgerald
C. These f therapies f are f active f against f influenza f A f and f B.
Tertiary fprevention fmeasures fare fpart fof fthe fmanagement D. The fuse fof fthese fproducts fis fan facceptable falternative
fof fan festablished fdisease. fThe fgoal fis fto fminimize fto finfluenza fvaccine.
fdisease- fassociated fcomplications fand fthe fnegative fhealth
14. Which fof fthe ffollowing fstatements fbest fdescribes
feffects fof fthe fconditions fto fthe fpatient. fExamples finclude
fzanamivir f(Relenza) for foseltamivir f(Tamiflu) fuse fin
fmedications fand flifestyle fmodification fto fnormalize fblood
fthe fcare fof fpatients fwith for fat frisk ffor finfluenza?
fglucose flevels fin findividuals fwith fdiabetes fmellitus fand fin
A. Initiation fof ftherapy fearly fin facute finfluenza fillness
fconjunction fwith fthe ftreatment fof fheart ffailure, faimed fat
fcan fhelp fminimize fthe fseverity fof fdisease fwhen
fimproving for fmini- fmizing fdisease-related fsymptoms.
fthe fillness fis fcaused fby fa fnonresistant fviral
DISCUSSION f SOURCES fstrain.
http://www.cdc.gov/excite/skincancer/mod13.htm, Centers for B. The fprimary findication fis fin fpreventing finfluenza fA
fDisease f Control fand f Prevention: f Levels fof f Prevention fduring foutbreaks.
http://www.niaid.nih.gov/topics/pages/communityimmunity.aspx, C. The f drugs f are f active f only f against f influenza f B.
f National fInstitute fof fAllergy fand fInfectious fDisease: D. The fuse fof fthese fmedications fis fan facceptable
fCommunity fImmunity falter- fnative fto finfluenza fvaccine.
, Section f1: fPreventive fServices fRecommended fby fthe fUSPSTF
The fU.S. fPreventive fServices fTask fForce f(USPSTF) frecommends fthat fclinicians fdiscuss fthese fpreventive fservices fwith feligible fpatients fand foffer fthem fas
fa fpriority. fAll fthese fservices fhave fbeen fgiven f―A‖ for fa f―B‖ f(recommended) fgrade ffrom fthe fTask fForce.
Adults Special fPopulations
Recommendation
Men Women Pregnant fWomen Children
Abdominal fAortic fAneurysm, f Screening
Alcohol fMisuse fScreening fand fBehavioral fCounseling
fInterventions
C fH fA fP fT fE fR
Asymptomatic fBacteriuria fin fAdults, fScreening
Breast fand fOvarian fCancer fSusceptibility, fGenetic fRisk
fAssessment fand fBRCA fMutation fTesting
f f
Breast fCancer, fScreening
1
Breastfeeding, fPrimary fCare fInterventions fto fPromote
Cervical fCancer, fScreening
Health f Promotion f and f Disease
Prevention
Chlamydial fInfection, fScreening
Colorectal fCancer, f Screening
Congenital f Hypothyroidism, f Screening
Depression fin fAdults, fScreening
Diabetes fMellitus f(Type f2) fin fAdults, fScreening
Folic fAcid fto fPrevent fNeural fTube fDefects
Gonococcal fOphthalmia fNeonatorum, fPreventive
fMedication
Figure f1-1 fPreventive fservices frecommended fby fthe fU.S. fPreventive fServices fTask fForce f(USPSTF). fAvailable fat fhttp://www.ahrq.gov/clinic/
fpocketgd2012/gcp12s1.htm.
Continued
3
f f f
Examination and Practice Preparation
f f f f f
Testbank by Margaret A. Fitzgerald
f f f f f
,HealthPromotion f
and Disease Prevention
f f
6. Active f immunity f is f defined f as:
A. resistance f developed f in f response f to f an f antigen.
B. immunity fconferred fby fan fantibody fproduced fin
fanother fhost.
1. An fexample fof fa fprimary fprevention fmeasure ffor fa78- C. the fresistance fof fa fgroup fto fan finfectious fagent.
fyear-old fman f with fchronic f obstructive
D. defense fagainst fdisease facquired fnaturally fby fthe
fpulmonary fdisease fis:
finfant ffrom fthe fmother.
A. reviewing f the f use f of f prescribed f medications.
B. conducting f a f home f survey f to f minimize f fall f risk. 7. Which fof fthe ffollowing fis fusually fviewed fas fthe fmost
C. checking fFEV1 f(force fexpired fvolume fat f1 fsecond) fcost-effective fform fof fhealthcare?
fto fFVC f(forced fvital fcapacity) fratio. A. primary f prevention
D. ordering ffecal foccult fblood ftest f(FOBT). B. secondary f prevention
C. tertiary f prevention
2. Which fof fthe ffollowing fis fan fexample fof fa fprimary fpreven- D. cancer-reduction f measures
ftion factivity fin fa f76-year-old fwoman fwith fosteoporosis?
A. bisphosphonate f therapy 8. An f18-year-old fwoman fwith fallergic frhinitis fpresents ffor
B. calcium f supplementation fprimary fcare. fShe fis fsexually factive fwith fa fmale fpartner
C. ensuring fadequate fillumination fin fthe fhome fand fis f1 fyear fpost-coitarche; fduring fthis ftime fshe fhad
fhad ftwo fsex fpartners. fAn fexample fof fa fprimary
D. use fof fa fback fbrace
fprevention factivity ffor fthis fpatient fis:
3. Secondary fprevention fmeasures ffor fa f78-year-old fman A. screening f for f sexually f transmitted f infection.
fwith fchronic fobstructive fpulmonary fdisease finclude:
B. counseling f about f safer f sexual f practices.
A. screening ffor fmood fdisorders. C. prescribing f therapies f for f minimizing f allergy.
B. administering f influenza f vaccine.
D. obtaining f a f liquid-based f Papanicolaou f (Pap) f test.
C. obtaining f a f serum f theophylline f level.
D. advising fabout fappropriate fuse fof fcar fpassenger 9. When fa fcritical fportion fof fa fcommunity fis fimmunized
frestraints. fagainst fa fcontagious fdisease, fmost fmembers fof fthe
fcom- fmunity, feven fthe funimmunized, fare fprotected
4. Tertiary fprevention fmeasures ffor fa f69-year-old fwoman fagainst fthat fdisease fbecause fthere fis flittle fopportunity
fwith fheart ffailure finclude:
ffor fan foutbreak. fThis fis fknown fas immunity.
A. administering f antipneumococcal f vaccine. A. passive
B. adjusting f therapy f to f minimize f dyspnea. B. humoral
C. surveying f skin f for f precancerous f lesions. C. epidemiologic
D. reviewing f safe f handling f of f food. D. community
5. Which f of f the f following f products f provides f passive
immunity?
f f f f
f 1. f B. 4. f B. 7. f A.
2. f C. 5. f A. 8. f B.
3. f A. 6. f A. 9. f D.
1
,2 C fHfA fP fT fE fR f f 1 ■ f f Health f Promotion f and f Disease f Prevention
Primary fprevention fmeasures finclude factivities fprovided
fto findividuals fto fprevent fthe fonset for facquisition fof fa fgiven
fdisease. fThe fgoal fof fprimary fprevention fmeasures fis fto fspare
findividuals fthe fsuffering, fburden, fand fcost fassociated fwith fthe
clinical fcondition fand fis fthe ffirst flevel fof fhealthcare. fAn fex- 10. When fadvising fa fpatient fabout finjectable finfluenza fim-
fample fis fhealth-protecting feducation fand fcounseling, fsuch fmunization, fthe fnurse fpractitioner f(NP) fconsiders fthe
fas fencouraging fthe fuse fof fcar frestraints fand fbicycle ffollowing fabout fthe fuse fof fthis fvaccine:
fhelmets, fcounseling fabout fsafer fsexual fpractices, fand A. Its fuse fis fnot frecommended fin fsickle fcell fanemia.
fproviding finfor- fmation fon faccident fand ffall fprevention. B. Its fuse fis flimited fto fchildren folder fthan f2 fyears.
fGiven fits ffocus fon fpreventing fillness for finjury, fprimary C. Its f use f is f limited f due f to f containing f live f virus.
fprevention fis fusually fviewed fas fthe fmost feffective fform D. Its fuse fis frecommended ffor fvirtually fall fmembers fof
fof fhealthcare. fthe fpopulation.
Immunizations fand fchemoprophylaxis fare falso fexam-
fples fof fprimary fprevention fmeasures. fActive fimmunization
11. A fmiddle-aged fman fwith fchronic fobstructive fpul-
fmonary fdisease fwho fis fabout fto freceive finjectable fin-
fthrough fthe fuse fof fvaccines fprovides flong-term fprotection
ffluenza fvaccine fshould fbe fadvised fthat:
ffrom fdisease. fIn fherd for fcommunity fimmunity, fa
A. it fis fmore fthan f90% feffective fin fpreventing finfluenza.
fsignificant fportion fof fa fgiven fpopulation fhas fimmunity
fagainst fan finfec- ftious fagent; fthe flikelihood fthat fthe
B. its fuse fis fcontraindicated fin fthe fpresence fof fpsoriasis
fvulgaris.
fsusceptible fportion fof fthe fgroup fwould fbecome finfected fis
C. localized freactions fsuch fas fsoreness fand fredness fat
fminimized f(Fig. f1–1). fPas- fsive fimmunity fis fprovided fwhen
fthe fsite fof fthe fimmunization fare ffairly
fa fperson freceives fselect fan- ftibodies, fusually fvia fthe
fcommon.
fadministration fof fimmune fglobulin f(IG), fafter fexposure fto
fan finfective fagent. fThis fimmunity fis ftemporary fand
D. a fshort, fintense, fflulike fsyndrome ftypically foccurs
fafter fimmunization.
frequires fthe fpatient fto fpresent fpost-exposure; fthe fprotection
fprovided fby fIG fusually fstarts fwithin fhours f of freceiving fthe 12. A f44-year-old fwoman fwith fasthma fpresents fasking ffor
fdoses fand flasts fa fnumber fof fmonths. fThe fuse fof fvaccines fto fa f‚flu fshot.‛ fShe fis fseen ftoday ffor fan furgent fcare fvisit, fis
fproduce flasting fdisease fprotection fis fpreferred fto fpassive fdiagnosed fwith fa flower furinary ftract finfection, fand fis
fimmunization fthrough fthe fuse fof fIG. fAnother fexam- fple fof fprescribed ftrimethoprim-sulfamethoxazole. fShe fis
fpassive fimmunity fis fthe facquisition fof fdisease fprotec- ftion fwithout ffever for fgastrointestinal fupset fwith fstable
fprovided ffrom fmother fto funborn fchild fvia fthe fplacenta. frespiratory fstatus. fYou finform fher fthat fshe:
fSecondary fprevention fmeasures finclude factivities fprovided A. should freturn ffor fthe fimmunization fafter fcomplet-
fto fidentify fand ftreat fasymptomatic fpersons fwho fhave frisk ffac- fing fher fantibiotic ftherapy.
ftors ffor fa fgiven fdisease for fin fpreclinical fdisease. fExamples fin- B. would flikely fdevelop fa fsignificant freaction fif fimmu-
fclude fscreening fexaminations ffor fpreclinical fevidence fof fnized ftoday.
fcancer, fsuch fas fmammography fand fcervical fexamination fwith C. can f receive f the f immunization f today.
f a fPapanicolaou ftest. fOther fexamples fof fsecondary D. is fnot fa fcandidate ffor fany fform fof finfluenza fvaccine.
fprevention factivities finclude fscreening ffor fclinical fconditions
13. Which fof fthe ffollowing fstatements fbest fdescribes
fwith fa fpro- ftracted fasymptomatic fperiod, fsuch fas fa fblood
famantadine for frimantadine fuse fin fthe fcare fof
fpressure fmeas- furement fto fdetect fhypertension fand fa flipid
fpatients fwith for fat frisk ffor finfluenza?
fprofile fto fdetect fhyperlipidemia f(Table f1–1).
A. Significant fresistance fto fselect fstrains fof finfluenza
See ffull fcolor fimages fof fthis ftopic flimits fthe fusefulness fof fthese fmedications.
fon f DavisPlus f at B. The fprimary faction fof fthese ftherapies fis fin fprevent-
f http://davisplus.fadavis.com f|
fing finfluenza fA fduring foutbreaks.
fKeyword: fFitzgerald
C. These f therapies f are f active f against f influenza f A f and f B.
Tertiary fprevention fmeasures fare fpart fof fthe fmanagement D. The fuse fof fthese fproducts fis fan facceptable falternative
fof fan festablished fdisease. fThe fgoal fis fto fminimize fto finfluenza fvaccine.
fdisease- fassociated fcomplications fand fthe fnegative fhealth
14. Which fof fthe ffollowing fstatements fbest fdescribes
feffects fof fthe fconditions fto fthe fpatient. fExamples finclude
fzanamivir f(Relenza) for foseltamivir f(Tamiflu) fuse fin
fmedications fand flifestyle fmodification fto fnormalize fblood
fthe fcare fof fpatients fwith for fat frisk ffor finfluenza?
fglucose flevels fin findividuals fwith fdiabetes fmellitus fand fin
A. Initiation fof ftherapy fearly fin facute finfluenza fillness
fconjunction fwith fthe ftreatment fof fheart ffailure, faimed fat
fcan fhelp fminimize fthe fseverity fof fdisease fwhen
fimproving for fmini- fmizing fdisease-related fsymptoms.
fthe fillness fis fcaused fby fa fnonresistant fviral
DISCUSSION f SOURCES fstrain.
http://www.cdc.gov/excite/skincancer/mod13.htm, Centers for B. The fprimary findication fis fin fpreventing finfluenza fA
fDisease f Control fand f Prevention: f Levels fof f Prevention fduring foutbreaks.
http://www.niaid.nih.gov/topics/pages/communityimmunity.aspx, C. The f drugs f are f active f only f against f influenza f B.
f National fInstitute fof fAllergy fand fInfectious fDisease: D. The fuse fof fthese fmedications fis fan facceptable
fCommunity fImmunity falter- fnative fto finfluenza fvaccine.
, Section f1: fPreventive fServices fRecommended fby fthe fUSPSTF
The fU.S. fPreventive fServices fTask fForce f(USPSTF) frecommends fthat fclinicians fdiscuss fthese fpreventive fservices fwith feligible fpatients fand foffer fthem fas
fa fpriority. fAll fthese fservices fhave fbeen fgiven f―A‖ for fa f―B‖ f(recommended) fgrade ffrom fthe fTask fForce.
Adults Special fPopulations
Recommendation
Men Women Pregnant fWomen Children
Abdominal fAortic fAneurysm, f Screening
Alcohol fMisuse fScreening fand fBehavioral fCounseling
fInterventions
C fH fA fP fT fE fR
Asymptomatic fBacteriuria fin fAdults, fScreening
Breast fand fOvarian fCancer fSusceptibility, fGenetic fRisk
fAssessment fand fBRCA fMutation fTesting
f f
Breast fCancer, fScreening
1
Breastfeeding, fPrimary fCare fInterventions fto fPromote
Cervical fCancer, fScreening
Health f Promotion f and f Disease
Prevention
Chlamydial fInfection, fScreening
Colorectal fCancer, f Screening
Congenital f Hypothyroidism, f Screening
Depression fin fAdults, fScreening
Diabetes fMellitus f(Type f2) fin fAdults, fScreening
Folic fAcid fto fPrevent fNeural fTube fDefects
Gonococcal fOphthalmia fNeonatorum, fPreventive
fMedication
Figure f1-1 fPreventive fservices frecommended fby fthe fU.S. fPreventive fServices fTask fForce f(USPSTF). fAvailable fat fhttp://www.ahrq.gov/clinic/
fpocketgd2012/gcp12s1.htm.
Continued
3
